Form 4: BioXcel Therapeutics Executive Javier Rodriguez Reports Stock Transactions
SEC Form 4
Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc., reports the vesting and acquisition of common stock through restricted stock units.
Summary
- On March 14, 2025, Javier Rodriguez acquired 31 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- On March 15, 2025, Rodriguez acquired 34 shares of common stock through the vesting of additional RSUs.
- These transactions are related to RSUs granted in March 2022 and March 2023, which vest quarterly subject to continuous employment.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they relate to executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| March 15, 2023 | Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| March 14, 2025 | Acquisition of 31 shares of common stock through RSU vesting. |
| March 15, 2025 | Acquisition of 34 shares of common stock through RSU vesting. |
| March 17, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.